WallStSmart

Auna S.A. (AUNA)vsJohnson & Johnson (JNJ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 2031% more annual revenue ($96.36B vs $4.52B). JNJ leads profitability with a 21.8% profit margin vs 1.5%. AUNA trades at a lower P/E of 16.7x. JNJ earns a higher WallStSmart Score of 59/100 (C).

AUNA

Hold

49

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 6.0Quality: 3.5
Piotroski: 3/9Altman Z: 1.19

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AUNA.

JNJSignificantly Overvalued (-71.4%)

Margin of Safety

-71.4%

Fair Value

$135.80

Current Price

$232.77

$96.97 premium

UndervaluedFair: $135.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AUNA2 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

P/E RatioValuation
16.7x8/10

Attractively priced relative to earnings

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$536.54B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
25.9%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
21.8%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

Areas to Watch

AUNA4 concerns · Avg: 3.0/10
Market CapQuality
$333.25M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
1.5%3/10

1.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
25.8x4/10

Moderate valuation

PEG RatioValuation
2.912/10

Expensive relative to growth rate

EPS GrowthGrowth
-52.9%2/10

Earnings declined 52.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : AUNA

The strongest argument for AUNA centers on Price/Book, P/E Ratio. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.

Bear Case : AUNA

The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.19 is elevated, increasing financial risk. Thin 1.5% margins leave little buffer for downturns.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AUNA profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

AUNA carries more volatility with a beta of 1.03 — expect wider price swings.

AUNA is growing revenue faster at 13.0% — sustainability is the question.

JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (59/100 vs 49/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Auna S.A.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Auna S.A. is a leading telecommunications and digital services provider in Latin America, offering a diverse range of integrated solutions that enhance connectivity for both residential and business clients. The company's extensive portfolio includes high-speed internet, television, and mobile services, underscoring its commitment to innovation and superior customer experience. Auna's robust infrastructure and strategic positioning enable it to capitalize on the increasing demand for advanced telecommunications solutions, making it an attractive investment opportunity for institutional investors seeking exposure to the region's expanding digital economy.

Visit Website →

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?